Caitlyn Stulpin

People with CMV have increased risk for TB, review finds

The results of a systematic review and meta-analysis suggest there is an increased risk for tuberculosis among people with cytomegalovirus infection, researchers reported in The Lancet.

Read More →

Less than half of people with latent TB in the US initiate therapy

Researchers uncovered gaps in the care cascade for latent tuberculosis in the United States, including that less than half of people diagnosed with latent TB in 2016 and 2017 initiated treatment.

Read More →

Study uncovers high rate of subclinical TB among people with HIV

The incidence of subclinical tuberculosis among people with HIV in a South African study was similar to the incidence of clinical TB, suggesting that guidelines recommending symptom-based screening may need to be updated, researchers said.

Read More →

CDC recommends 4-month regimen for drug-susceptible TB

The CDC published a recommendation and interim guidance in MMWR for a 4-month regimen to treat patients aged 12 years or older with drug-susceptible pulmonary tuberculosis.

Read More →

Study reveals association between CMV and latent TB

U.S. data revealed that cytomegalovirus was independently associated with latent tuberculosis infection, and both were associated with high levels of C-reactive protein, suggesting enhanced systemic inflammation, researchers reported.

Read More →

Nucleic acid amplification testing not performed in nearly half of confirmed US TB cases

The use of nucleic acid amplification testing for tuberculosis increased in the United States between 2011 and 2017, although nearly half of U.S. TB cases did not include one of the tests, according to a study.

Read More →

M. tuberculosis prosthetic joint infection rare but possible in some patients

Although prosthetic joint infections caused by Mycobacterium tuberculosis are rare, they may occur in immunocompromised patients or in people from regions where tuberculosis is endemic, researchers reported in a recent study.

Read More →

4-month TB regimen noninferior to 6-month regimen in people with HIV

A 4-month daily regimen of rifapentine and moxifloxacin was noninferior to the standard 6-month regimen for tuberculosis treatment among people with HIV enrolled in a phase 3 clinical trial, researchers reported at CROI.

Read More →

In shadow of COVID-19, TB vaccine research enters new era

In less than a year, scientists were able to develop several efficacious vaccines against COVID-19.

Read More →

Self-administered 3HP associated with high treatment completion for latent TB

Self-administered isoniazid-rifapentine taken once weekly — a regimen called 3HP — was associated with higher treatment completion rates for latent tuberculosis infection compared with daily rifampin, according to a study.

Read More →

Page 1 of 3 · Total posts: 10

1 2 Last→